The Lonza Board of Directors today announced the nomination of Stephen Fry as an Independent Member of the Board. Subject to his election at the Lonza Group Annual General Meeting (AGM) in May 2026, Stephen will also be appointed a member of the People and Governance Committee and the Audit and Compliance Committee.

Stephen brings deep pharmaceutical industry experience, a global leadership perspective and strong expertise to the Board. Stephen spent more than three decades at Eli Lilly and Company, where he held a broad range of international, operational and executive leadership roles, ultimately serving as Executive Vice President and Chief Human Resources Officer for 12 years. In this role, he led large‑scale organizational transformation, shaped high‑performance cultures and helped navigate the company through significant change. Stephen is also a Member of the Board of Trustees at the University of Indianapolis (US).

Jean-Marc Huët, Chairman of the Board, Lonza, commented: “The Board of Directors extends its warmest congratulations to Stephen for his nomination to the Board. Stephen brings extensive international experience, combined with a strong track record in organizational governance, succession planning and people strategy development, all of which form a valuable complementary fit with the capabilities of our other Board members. Stephen will play an important role in helping develop and embed our performance culture. This will support our ambition to attract and retain world-leading talent and bring our high-performing teams to the next level.”